Free Trial

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals logo
$449.00 +2.85 (+0.64%)
As of 10:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
14
Buy
16

Based on 30 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 14 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$515.04
14.71% Upside
According to the 30 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $515.04. The highest price target for VRTX is $586.00, while the lowest price target for VRTX is $423.00. The average price target represents a forecasted upside of 14.71% from the current price of $449.00.
Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

Sign Up

VRTX Analyst Ratings Over Time

TypeCurrent Forecast
6/10/24 to 6/10/25
1 Month Ago
5/11/24 to 5/11/25
3 Months Ago
3/12/24 to 3/12/25
1 Year Ago
6/11/23 to 6/10/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
Hold
14 Hold rating(s)
13 Hold rating(s)
10 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$515.04$515.04$506.70$438.62
Forecasted Upside14.71% Upside21.10% Upside2.28% Upside-9.24% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Vertex Pharmaceuticals Stock vs. The Competition

TypeVertex PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside15.44% Upside5,918.79% Upside13.46% Upside
News Sentiment Rating
Positive News

See Recent VRTX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/23/2025Erste Group Bank
3 of 5 stars
H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/7/2025Wolfe Research
4 of 5 stars
A. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/6/2025The Goldman Sachs Group
3 of 5 stars
 Reiterated RatingBuy ➝ Buy
5/6/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/6/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
5/6/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Greg Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSector Perform ➝ Sector Perform$450.00 ➝ $442.00+1.69%
5/6/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform ➝ Sector Perform$420.00 ➝ $423.00-2.68%
5/6/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$462.00 ➝ $464.00+6.41%
5/6/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$512.00 ➝ $515.00+16.15%
5/6/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$535.00 ➝ $535.00+6.96%
5/6/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$550.00 ➝ $503.00+0.56%
5/6/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/31/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ying Huang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$555.00 ➝ $567.00+15.08%
2/11/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Whitney Ijem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold$408.00 ➝ $424.00-7.59%
2/11/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$460.00 ➝ $520.00+13.01%
2/11/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gena Wang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$435.00 ➝ $467.00+1.35%
2/11/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$550.00 ➝ $550.00+17.03%
1/31/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$545.00+12.55%
1/30/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$460.00 ➝ $460.00+4.19%
1/27/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$535.00 ➝ $533.00+20.72%
12/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
12/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$490.00 ➝ $494.00+6.53%
12/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$500.00 ➝ $550.00+19.02%
11/14/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$575.00+16.25%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Bristow
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$562.00 ➝ $586.00+17.77%
10/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
8/2/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$450.00 ➝ $558.00+13.08%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$450.00 ➝ $500.00+1.60%
6/27/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Chesney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$545.00+14.98%
6/17/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$465.00 ➝ $550.00+15.48%
4/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$438.00+10.17%
2/2/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$325.00-25.27%
1/31/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
6/26/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:18 AM ET.


Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 9, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • The current stock price is around $446, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals has received multiple recent upgrades from analysts, indicating positive sentiment and potential for stock appreciation.
  • The company reported a year-over-year revenue increase of 2.6%, showcasing its ability to grow despite market challenges.
  • Vertex Pharmaceuticals has a strong market capitalization of approximately $115 billion, reflecting its stability and investor confidence.
  • With a consensus price target of around $515, analysts suggest there is potential upside for investors based on current valuations.

Vertex Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • The company recently missed earnings expectations, reporting $4.06 EPS compared to the consensus estimate of $4.29, which may raise concerns about its profitability.
  • Vertex Pharmaceuticals has a negative return on equity of 2.02%, indicating that the company is not generating profit from its equity, which could deter potential investors.
  • The stock has a high price-to-earnings ratio, suggesting that it may be overvalued compared to its earnings, which could lead to price corrections.
  • Recent downgrades from some analysts, including a shift from "outperform" to "peer perform," may signal caution regarding the stock's future performance.
  • The company has a negative net margin of 4.86%, indicating that it is currently spending more than it earns, which could impact future growth prospects.

VRTX Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $515.04, with a high forecast of $586.00 and a low forecast of $423.00.

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 14 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRTX shares.

According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 14.71% based on their 12-month stock forecasts.

Over the previous 90 days, Vertex Pharmaceuticals's stock had 3 downgrades by analysts.

Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.57 while the average consensus rating score for "medical" companies is 2.81. Learn more on how VRTX compares to other companies.


This page (NASDAQ:VRTX) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners